Hongchao Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hongchao Zheng has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Daniel H. Appella
Synthetic Bioactive Molecules Section, Laboratory of Bioorganic Chemistry (LBC), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, USA
2 shared publications - Eylon Yavin
Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Hadassah Ein-Kerem, Jerusalem 91120, Israel
2 shared publications - Huda Nazzal
School of Pharmacy, Institute for Drug Research, The Hebrew University of Jerusalem, Hadassah Ein-Kerem, Jerusalem 91120, Israel
1 shared publication - Odelia Tepper
The Hebrew University of Jerusalem Hadassah Ein-Kerem
1 shared publication - Rawan Mahajna
Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Hadassah Ein-Kerem, Jerusalem 91120, Israel
1 shared publication - Reuven Reich
Institute of Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel
1 shared publication
Latest Publications
- Open Access
- 22 May 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (6) , 609
Detecting the FLJ22447 lncRNA in Ovarian Cancer with Cyclopentane-Modified FIT-PNAs (cpFIT-PNAs)
Ovarian cancer (OC) is one of the most lethal gynecologic cancers that is typically diagnosed at the very late stage of disease progression. Thus, there is an unmet need to develop diagnostic probes for early detection of OC. One approach may rely on RNA as a molecular biomarker. In this regard, FLJ22447 lncRNA is an RNA biomarker that is over-expressed in ovarian cancer (OC) and in cancer-associated fibroblasts (CAFs). CAFs appear early on in OC as they provide a metastatic niche for OC progression. FIT-PNAs (forced intercalation-peptide nucleic acids) are DNA analogs that are designed to fluoresce upon hybridization to their complementary RNA target sequence. In recent studies, we have shown that the introduction of cyclopentane PNAs into FIT-PNAs (cpFIT-PNA) results in superior RNA sensors. Herein, we report the design and synthesis of cpFIT-PNAs for the detection of this RNA biomarker in living OC cells (OVCAR8) and in CAFs. cpFIT-PNA was compared to FIT-PNA and the cell-penetrating peptide (CPP) of choice was either a simple one (four L-lysines) or a CPP with enhanced cellular uptake (CLIP6). The combination of CLIP6 with cpFIT-PNA resulted in a superior sensing of FLJ22447 lncRNA in OVCAR8 cells as well as in CAFs. Moreover, incubation of CLIP6-cpFIT-PNA in OVCAR8 cells leads to a significant decrease (ca. 60%) in FLJ22447 lncRNA levels and in cell viability, highlighting the potential theranostic use of such molecules.
- 22 May 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (6) , 609
Open AccessDetecting the FLJ22447 lncRNA in Ovarian Cancer with Cyclopentane-Modified FIT-PNAs (cpFIT-PNAs)
Ovarian cancer (OC) is one of the most lethal gynecologic cancers that is typically diagnosed at the very late stage of disease progression. Thus, there is an unmet need to develop diagnostic probes for early detection of OC. One approach may rely on RNA as a molecular biomarker. In this regard, FLJ22447 lncRNA is an RNA biomarker that is over-expressed in ovarian cancer (OC) and in cancer-associated fibroblasts (CAFs). CAFs appear early on in OC as they provide a metastatic niche for OC progression. FIT-PNAs (forced intercalation-peptide nucleic acids) are DNA analogs that are designed to fluoresce upon hybridization to their complementary RNA target sequence. In recent studies, we have shown that the introduction of cyclopentane PNAs into FIT-PNAs (cpFIT-PNA) results in superior RNA sensors. Herein, we report the design and synthesis of cpFIT-PNAs for the detection of this RNA biomarker in living OC cells (OVCAR8) and in CAFs. cpFIT-PNA was compared to FIT-PNA and the cell-penetrating peptide (CPP) of choice was either a simple one (four L-lysines) or a CPP with enhanced cellular uptake (CLIP6). The combination of CLIP6 with cpFIT-PNA resulted in a superior sensing of FLJ22447 lncRNA in OVCAR8 cells as well as in CAFs. Moreover, incubation of CLIP6-cpFIT-PNA in OVCAR8 cells leads to a significant decrease (ca. 60%) in FLJ22447 lncRNA levels and in cell viability, highlighting the potential theranostic use of such molecules.
- Open Access
- 15 September 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 59 (77) , 11593
Correction: Cyclopentane FIT-PNAs: bright RNA sensors
Correction for ‘Cyclopentane FIT-PNAs: bright RNA sensors’ by Odelia Tepper et al., Chem. Commun., 2021, 57, 540–543, https://doi.org/10.1039/D0CC07400D.
- 15 September 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 59 (77) , 11593
Open AccessCorrection: Cyclopentane FIT-PNAs: bright RNA sensors
Correction for ‘Cyclopentane FIT-PNAs: bright RNA sensors’ by Odelia Tepper et al., Chem. Commun., 2021, 57, 540–543, https://doi.org/10.1039/D0CC07400D.